secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001387131-23-003349
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix reports FY2022 net loss of $116.9M; cash $120.2M; pipeline milestones ahead
--------------------------------------------------------------------------------

- Net loss $34.1M in Q4 2022 ($0.56/share) vs $29.6M ($2.08) in Q4 2021; FY net loss $116.9M ($3.27) vs $92.3M ($8.10).
- Cash and equivalents $120.2M at Dec 31, 2022, down from $178.7M a year ago; cash used in operations $98.1M in FY2022.
- Repurchased 15.7M shares under $12.5M program; new $12.5M program approved Jan 2023 with 1M shares bought.
- Interim analysis for Phase 3 fibromyalgia study (TNX-102 SL) expected Q2 2023; topline Q4 2023.
- Appointed R. Newcomb Stillwell to Board; acquired antiviral assets from Healion Bio; licensed monoclonal antibodies from Columbia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123003349/0001387131-23-003349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123003349/tnxp-8k_031323.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-003349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer